- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
- 10-K Annual report
- 10.1 Form of Performance-based Stock Option Agreement Under the NPS Pharmaceutical, Inc. 1998 Stock Option Plan.
- 10.3 Change In Control Severance Pay Plan, As Amended
- 10.33 First Amendment to the Employment Agreement with Francois Nader
- 10.34 Second Amendment to the Employment Agreement with Francois Nader
- 10.35 Employment Agreement with Roger Garceau
- 12.1 Computation Ratio of Earnings Available to Cover Fixed Charges
- 23.1 Consent of Independent Registered Public Accounting Firm
- 31.1 CEO 302 Certificate
- 31.2 CFO 302 Certificate
- 32 906 Certificate
- PDF 10-K
- 10.1 Form of Performance-based Stock Option Agreement Under the NPS Pharmaceutical, Inc. 1998 Stock Option Plan.
- 10.3 Change In Control Severance Pay Plan, As Amended
- 10.33 First Amendment to the Employment Agreement with Francois Nader
- 10.34 Second Amendment to the Employment Agreement with Francois Nader
- 10.35 Employment Agreement with Roger Garceau
- 12.1 Computation Ratio of Earnings Available to Cover Fixed Charges
- 23.1 Consent of Independent Registered Public Accounting Firm
- 31.1 CEO 302 Certificate
- 31.2 CFO 302 Certificate
- 32 906 Certificate
Exhibit 10.34
SECOND AMENDMENT
TO
EMPLOYMENT AGREEMENT
- The Employment Agreement (the "Agreement") entered into as of March 17, 2008, by and between NPS Pharmaceuticals, Inc. and Francois Nader, M.D., as previously amended, is hereby further amended as follows:
- Section III.c is hereby amended by adding the following at the end thereof:
- Except as amended herein, the Agreement is confirmed in all other respects.
"Notwithstanding the foregoing, commencing January 15, 2009, the option grant provided by this Section III.c shall be made on an annual basis, on the first scheduled meeting of the Compensation Committee of the calendar year, rather than on a quarterly basis; provided, however, that the annual option grant to be made on January 15, 2009 shall cover only Sixty-Seven Thousand Five Hundred (67,500) stock options, as the first quarterly installment grant of Twenty-Two Thousand Five Hundred (22,500) stock options will have been made on January 15, 2009."
Executed this 21st day of January, 2009 by the parties hereto.
NPS PHARMACEUTICALS, INC.
By:/s/ Andrew Rackear
Andrew Rackear
General Counsel & SVP, Legal Affairs
/s/ Francois Nader
Francois Nader, M.D.